Ascrinvacumab
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | activin receptor-like kinase 1 |
| Clinical data | |
| Other names | PF-03446962 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6396H9850N1694O2012S44 |
| Molar mass | 144.1 kg/mol g·mol−1 |
This drug was developed by Pfizer Inc.
References
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone ("-os-", "-s(o)-") |
| ||||||||
| Musculoskeletal ("-mul-") |
| ||||||||
| Circulatory ("-c(i[r])-") |
| ||||||||
| Neurologic ("-ne(u)(r)-") |
| ||||||||
| Angiogenesis inhibitor ("-anibi-") |
| ||||||||
| Growth factor ("-gr(o)-") |
| ||||||||
| |||||||||
TGFβ receptor superfamily modulators | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type I |
| ||||||||||||||
| Type II |
| ||||||||||||||
| Type III |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
| |||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.